Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor
Gespeichert in:
| Veröffentlicht in: | Thrombosis and haemostasis 2000-04, Vol.83 (4), p.633-634 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 634 |
|---|---|
| container_issue | 4 |
| container_start_page | 633 |
| container_title | Thrombosis and haemostasis |
| container_volume | 83 |
| creator | Grossmann, R.E. Geisen, U. Schwender, S. Keller, F. |
| description | |
| doi_str_mv | 10.1055/s-0037-1613878 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1055_s_0037_1613878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10780333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-86e20fad7809642b0e175ab9aa64147febc84f58fe36b22d4919719174347b0d3</originalsourceid><addsrcrecordid>eNp1UUuO1DAUjBCIaQa2LJGXsMhgx47jLEc9DEQaAYLms7Oc5IV4lNgtP6dHs-MaXIIVJ-AonAS3uoUQEiur5Kp671Vl2WNGzxgty-eYU8qrnEnGVaXuZKuilFUuVf35braiXNBcFqI8yR4gXlPKpKjL-9kJo5WinPNV9mPtXbRu8QuSxg0LWu-IH8g76PzcWmdcJJemiz6Qj01jyNPXfuffww7cz-_PiHUkjkA2AUycIVGT0pC3Jto9uLFxJJvbLZCmacguGX-y0wRtMK7_9fUbkguLYBBIwuR8mnwaZlvfW0BivhjrMP6jOq7yMLs3mAnh0fE9zT5cvtisX-VXb1426_OrvOO1jLmSUNDB9OnWWoqipcCq0rS1MVIwUQ3QdkoMpRqAy7YoelGzumI1qwQXVUt7fpqdHXy74BEDDHob7GzCrWZU7-PXqPfx62P8SfDkINgu7Qz9X_RD3omQHwhxtDCDvvZLcOmE_xvaAx-70cRoFgh_TOMYUkUeLeoUjR4NzB6j2eMulZoaSB-hG-0OtEVcQCvF9Wzcgl2w26ilUIXG0d_oMc4T_w2asrvN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Grossmann, R.E. ; Geisen, U. ; Schwender, S. ; Keller, F.</creator><creatorcontrib>Grossmann, R.E. ; Geisen, U. ; Schwender, S. ; Keller, F.</creatorcontrib><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1055/s-0037-1613878</identifier><identifier>PMID: 10780333</identifier><language>eng</language><publisher>Germany: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Anaphylaxis - etiology ; Epistaxis - etiology ; Epistaxis - therapy ; Factor VIIa - administration & dosage ; Factor VIIa - therapeutic use ; Hematoma - etiology ; Hematoma - therapy ; Humans ; Infusions, Intravenous ; Isoantibodies - immunology ; Letters to the Editor ; Male ; Middle Aged ; Recombinant Fusion Proteins - administration & dosage ; Recombinant Fusion Proteins - therapeutic use ; Recurrence ; von Willebrand Diseases - classification ; von Willebrand Diseases - complications ; von Willebrand Diseases - immunology ; von Willebrand Diseases - therapy ; von Willebrand Factor - immunology</subject><ispartof>Thrombosis and haemostasis, 2000-04, Vol.83 (4), p.633-634</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-86e20fad7809642b0e175ab9aa64147febc84f58fe36b22d4919719174347b0d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0037-1613878.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1055/s-0037-1613878$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,780,784,3015,3016,27922,27923,54557,54558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10780333$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grossmann, R.E.</creatorcontrib><creatorcontrib>Geisen, U.</creatorcontrib><creatorcontrib>Schwender, S.</creatorcontrib><creatorcontrib>Keller, F.</creatorcontrib><title>Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><subject>Anaphylaxis - etiology</subject><subject>Epistaxis - etiology</subject><subject>Epistaxis - therapy</subject><subject>Factor VIIa - administration & dosage</subject><subject>Factor VIIa - therapeutic use</subject><subject>Hematoma - etiology</subject><subject>Hematoma - therapy</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Isoantibodies - immunology</subject><subject>Letters to the Editor</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Recurrence</subject><subject>von Willebrand Diseases - classification</subject><subject>von Willebrand Diseases - complications</subject><subject>von Willebrand Diseases - immunology</subject><subject>von Willebrand Diseases - therapy</subject><subject>von Willebrand Factor - immunology</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UUuO1DAUjBCIaQa2LJGXsMhgx47jLEc9DEQaAYLms7Oc5IV4lNgtP6dHs-MaXIIVJ-AonAS3uoUQEiur5Kp671Vl2WNGzxgty-eYU8qrnEnGVaXuZKuilFUuVf35braiXNBcFqI8yR4gXlPKpKjL-9kJo5WinPNV9mPtXbRu8QuSxg0LWu-IH8g76PzcWmdcJJemiz6Qj01jyNPXfuffww7cz-_PiHUkjkA2AUycIVGT0pC3Jto9uLFxJJvbLZCmacguGX-y0wRtMK7_9fUbkguLYBBIwuR8mnwaZlvfW0BivhjrMP6jOq7yMLs3mAnh0fE9zT5cvtisX-VXb1426_OrvOO1jLmSUNDB9OnWWoqipcCq0rS1MVIwUQ3QdkoMpRqAy7YoelGzumI1qwQXVUt7fpqdHXy74BEDDHob7GzCrWZU7-PXqPfx62P8SfDkINgu7Qz9X_RD3omQHwhxtDCDvvZLcOmE_xvaAx-70cRoFgh_TOMYUkUeLeoUjR4NzB6j2eMulZoaSB-hG-0OtEVcQCvF9Wzcgl2w26ilUIXG0d_oMc4T_w2asrvN</recordid><startdate>20000401</startdate><enddate>20000401</enddate><creator>Grossmann, R.E.</creator><creator>Geisen, U.</creator><creator>Schwender, S.</creator><creator>Keller, F.</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20000401</creationdate><title>Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor</title><author>Grossmann, R.E. ; Geisen, U. ; Schwender, S. ; Keller, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-86e20fad7809642b0e175ab9aa64147febc84f58fe36b22d4919719174347b0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Anaphylaxis - etiology</topic><topic>Epistaxis - etiology</topic><topic>Epistaxis - therapy</topic><topic>Factor VIIa - administration & dosage</topic><topic>Factor VIIa - therapeutic use</topic><topic>Hematoma - etiology</topic><topic>Hematoma - therapy</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Isoantibodies - immunology</topic><topic>Letters to the Editor</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Recurrence</topic><topic>von Willebrand Diseases - classification</topic><topic>von Willebrand Diseases - complications</topic><topic>von Willebrand Diseases - immunology</topic><topic>von Willebrand Diseases - therapy</topic><topic>von Willebrand Factor - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grossmann, R.E.</creatorcontrib><creatorcontrib>Geisen, U.</creatorcontrib><creatorcontrib>Schwender, S.</creatorcontrib><creatorcontrib>Keller, F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grossmann, R.E.</au><au>Geisen, U.</au><au>Schwender, S.</au><au>Keller, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2000-04-01</date><risdate>2000</risdate><volume>83</volume><issue>4</issue><spage>633</spage><epage>634</epage><pages>633-634</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><cop>Germany</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>10780333</pmid><doi>10.1055/s-0037-1613878</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6245 |
| ispartof | Thrombosis and haemostasis, 2000-04, Vol.83 (4), p.633-634 |
| issn | 0340-6245 2567-689X |
| language | eng |
| recordid | cdi_crossref_primary_10_1055_s_0037_1613878 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Anaphylaxis - etiology Epistaxis - etiology Epistaxis - therapy Factor VIIa - administration & dosage Factor VIIa - therapeutic use Hematoma - etiology Hematoma - therapy Humans Infusions, Intravenous Isoantibodies - immunology Letters to the Editor Male Middle Aged Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Recurrence von Willebrand Diseases - classification von Willebrand Diseases - complications von Willebrand Diseases - immunology von Willebrand Diseases - therapy von Willebrand Factor - immunology |
| title | Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A59%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20Infusion%20of%20Recombinant%20Factor%20VIIa%20(NovoSeven%C2%AE)%20in%20the%20Treatment%20of%20a%20Patient%20with%20Type%20III%20von%20Willebrand%E2%80%99s%20Disease%20and%20Alloantibodies%20against%20von%20Willebrand%20Factor&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Grossmann,%20R.E.&rft.date=2000-04-01&rft.volume=83&rft.issue=4&rft.spage=633&rft.epage=634&rft.pages=633-634&rft.issn=0340-6245&rft.eissn=2567-689X&rft_id=info:doi/10.1055/s-0037-1613878&rft_dat=%3Cpubmed_cross%3E10780333%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10780333&rfr_iscdi=true |